GLSI — Greenwich Lifesciences Balance Sheet
0.000.00%
Last trade - 00:00- $155.44m
- $148.45m
- 37
- 14
- 76
- 37
Annual balance sheet for Greenwich Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.007 | 28.7 | 27.2 | 13.5 | 6.99 |
| Total Current Assets | 0.007 | 28.7 | 27.2 | 13.5 | 6.99 |
| Net Intangible Assets | |||||
| Total Assets | 0.027 | 28.7 | 27.2 | 13.5 | 6.99 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1.38 | 1.05 | 0.385 | 0.263 | 0.294 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.38 | 1.05 | 0.385 | 0.263 | 0.294 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -1.35 | 27.6 | 26.8 | 13.2 | 6.7 |
| Total Liabilities & Shareholders' Equity | 0.027 | 28.7 | 27.2 | 13.5 | 6.99 |
| Total Common Shares Outstanding |